Abstract
& EMG performed for suspected ALS must include at least three regions of the neuraxis to confirm a widespread pattern beyond regional damage from radiculopathies. & It is not uncommon for fasciculations to go unrecognized by the patient and only be noticed by a family member or physician. & Progression and spread of symptoms are hallmarks of ALS. & ALS is often described as painless, but muscle cramps can be quite uncomfortable and, at times, painful. & There are no specific tests for monomelic amyotrophy; therefore, initially, this disease may be difficult to distinguish from focal ALS. Over time monomelic amyotrophy will not progress and no upper motor neuron features manifest.
Charcot-Marie-Tooth Disease and Other Inherited Neuropathies
& Patients with a classic Charcot-Marie-Tooth disease type 1 phenotype and male-to-male transmission in the family who test negative for the PMP22 duplication should then be tested for Charcot-Marie-Tooth disease type 1B, which is the third most common cause of Charcot-Marie-Tooth disease type 1. & Dejerine-Sottas disease is currently used primarily to denote severe early-onset clinical phenotypes regardless of the inheritance pattern. These cases are usually associated with PMP22 duplication or point mutations, MPZ mutations, and, in rare cases, other Charcot-Marie-Tooth disease type 1 genes or recessive forms. & Charcot-Marie-Tooth disease type 2 (CMT2) accounts for approximately 25% to 30% of all Charcot-Marie-Tooth disease cases. However, this prevalence may be an underestimation, as only a minority of CMT2 patients have a molecular diagnosis (approximately 25%). & Most other axonal Charcot-Marie-Tooth disease types are of rare occurrence and difficult to diagnose. Relying on associated symptoms to narrow the list of genes to be tested is a common strategy in specialized centers. & The nomenclature ''intermediate Charcot-Marie-Tooth disease'' should be used to define families with individuals presenting with median motor nerve conduction velocities in the demyelinating range while other affected members demonstrate velocities in the axonal range. & Mutations in GJB1, MPZ, DNM2, YARS, IFN2, and GNB4 have all been associated with intermediate Charcot-Marie-Tooth disease and therefore should be tested in such cases. & Recessive forms of Charcot-Marie-Tooth disease are suspected in families with multiple affected siblings and asymptomatic parents or in patients with no family history but specific phenotypes. & Distal hereditary motor neuropathies are a distinct phenotype of inherited neuropathies, characterized by a length-dependent, slowly progressive, exclusively motor neuropathy. & Hereditary sensory and autonomic neuropathies designate phenotypes in which sensory or autonomic symptoms predominate, although a minor motor component can still be observed. & The most prevalent types of hereditary sensory and autonomic neuropathies are autosomal recessive, with congenital or early onset presentations. However, autosomal dominant forms are also seen, with later onset of symptoms. & As the technology develops and prices drop, next-generation sequencing will probably become the standard method for molecular diagnosis of patients with Charcot-Marie-Tooth disease, as it will soon be less expensive than sequencing multiple single genes using direct sequencing techniques. & Patients with inherited neuropathies are best managed by a multidisciplinary team of professionals, including genetic counselors, physical and occupational therapists, nurses, neurologists, orthopedic surgeons, and physiatrists. & The decision to have genetic testing or not should always rest with the patient. Reasons for pursuing a molecular diagnosis include family planning, etiologic elucidation of the neuropathy, eligibility to enroll in type-specific clinical trials, and application for some government benefits. Issues associated with testing, on the other hand, include psychological distress, social and work discrimination, and high financial cost of the test. & Patients with inherited neuropathies should be periodically screened for diseases that may exacerbate their impairment, including diabetes mellitus, hypothyroidism, vitamin deficiencies, and monoclonal gammopathies, and correction of any abnormality should be done promptly. & Assistive devices, including inserts and ankle-foot orthoses, and occupational therapy focused on developing tools and strategies to cope with activities of daily living, should be used to improve functionality and quality of life of patients with Charcot-Marie-Tooth disease. & Transthyretin familial amyloid polyneuropathy usually presents as a small fiber neuropathy around the third or fourth decade of life, which progresses to a large fiber sensorimotor severe neuropathy. Autonomic dysfunction is common, affecting the cardiovascular, gastrointestinal, and genitourinary systems. The disease progresses relentlessly, with patients usually dying within 10 years of diagnosis. & Metabolic disorders are another cause of multisystem diseases that also affect the peripheral nervous system. This group includes some leukodystrophies (metachromatic, Krabbe, adrenoleukodystrophy), peroxisomal diseases (Fabry, Refsum), lipoprotein deficiencies (Tangier, cerebrotendinous xanthomatosis), porphyrias, and mitochondrial diseases. 
Diabetic Neuropathies

Abstract
Purpose of Review:
This article provides an overview for understanding the diagnosis, pathogenesis, and management of diabetic neuropathy.
Recent Findings:
New information about the pathogenesis of diabetic neuropathy continues to emerge, which will lead to identifying new drug targets. It is clear that the natural history of diabetic neuropathy is changing and the rate of progression is slowing. This is likely because of a combination of earlier diagnosis, improved glycemic management, and improved control of related complications such as hyperlipidemia and hypertension. Early diagnosis is critical, and small fiber neuropathy or subclinical diabetic neuropathy may be reversed or significantly improved with appropriate intervention. The American Academy of Neurology recently published guidelines for the treatment of painful diabetic neuropathy.
Summary:
Diabetic neuropathy is common and can present with varied clinical presentations discussed in this article. Although treatment currently focuses on pain management, attention should be paid to potential risk factors for neuropathy. For example, glycemic control, hyperlipidemia, and hypertension should be managed with diet, exercise, and medications. Class I or II clinical studies indicate that pregabalin, duloxetine, amitriptyline, gabapentin, and opioids are effective in the management of diabetic neuropathic pain. to recognize acquired immune demyelinating neuropathies as they are generally responsive to immunosuppressive or immunomodulatory therapies.
Key Points
Recent Findings:
This article reviews recently developed early prognostic tools in Guillain-Barré syndrome and discusses the evolving understanding of chronic demyelinating phenotypes with differing treatment responsiveness.
Summary:
While weakness and numbness progress over 2 to 4 weeks in Guillain-Barré syndrome, they continue to evolve beyond 8 weeks in chronic inflammatory demyelinating polyradiculoneuropathy and over 4 to 8 weeks in subacute inflammatory demyelinating polyradiculoneuropathy. Acquired immune demyelinating neuropathies present uncommonly as variants with predominance of ocular, bulbar, sensory, autonomic, or motor manifestations in addition to regional variants, such as paraparetic acquired immune demyelinating neuropathies. Establishing the correct diagnosis is important as these immune disorders differ in response to corticosteroids and other immunosuppressive therapies.
Key Points
& The Landry-Guillain-Barré-Strohl syndrome, commonly referred to as Guillain-Barré syndrome (GBS), is an acute monophasic immune-mediated polyradiculoneuropathy with an incidence ranging from 1.1 to 1.8 per 100,000. & Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) begins most commonly with acroparesthesia, followed 7 to 10 days later by symmetric ascending weakness, which is associated with severe radicular lumbar and neuropathic pain in up to two & Diagnostic criteria for Guillain-Barré syndrome were proposed 2 decades ago and require laboratory support and exclusion of mimics. & It is critically important to obtain an initial forced vital capacity and negative inspiratory force on presentation of patients with Guillain-Barré syndrome as these predict incipient respiratory failure well before hypoxemia supervenes on pulse oximetry or arterial blood gas testing. & CSF evaluation in Guillain-Barré syndrome shows a nonspecifically elevated protein in 90% of cases in the absence of white blood cell elevation (less than 20/mm 3 ), the so-called albuminocytologic dissociation. CSF protein elevation may be delayed; in those with normal initial studies, a repeat lumbar puncture in 5 to 7 days may be supportive of the diagnosis. & Depending on the criteria, the sensitivity of nerve conduction study may be as low as 22% in early AIDP and rise to 87% at 5 weeks. Therefore, it is important not to delay treatment in patients who do not have supportive nerve conduction study findings. & A sural sparing pattern is observed in one-third of cases of Guillain-Barré syndrome, with normal sural sensory nerve action potential amplitude and reduced or absent median or ulnar sensory nerve action potential amplitude. & Distal compound muscle action potential duration prolongation beyond 8.5 ms was found in 5/13 (38%) of patients with AIDP with negative electrodiagnostic studies, and in only 9%of ALS cases. & If routine testing is not diagnostic in Guillain-Barré syndrome, it is important to test contralateral limb distal motor nerves, proximal nerves, and cranial nerves, or even to repeat nerve conduction studies in 3 to 5 days. & It is fundamental to provide excellent general supportive care in Guillain-Barré syndrome. & Overall, the guiding principle is not to overtreat dysautonomia in Guillain-Barré syndrome since blood pressure will often fluctuate. & Plasma exchange within 2 to 4 weeks of onset was the first treatment shown to be effective in Guillain-Barré syndrome based on randomized controlled trials. It reduces the time to walk unaided by 32 to 41 days and time on ventilator by 2 weeks. & IVIg was the second treatment shown to be effective in Guillain-Barré syndrome.
Both treatments (IVIg and plasma exchange) are equally effective at 4 weeks. & Plasma exchange followed by IVIg is not more effective than either therapy alone. & Oral corticosteroids are contraindicated in Guillain-Barré syndrome for concern of worse outcome. Adding IV methylprednisolone to IVIg is no better than placebo. & The mean time to onset of recovery of Guillain-Barré syndrome is 28 days and to complete recovery is 200 days. Most patients (80%) resume the ability to walk independently by 6 months, with some experiencing persistent long-term sensory or autonomic symptoms of varying severity. & Useful predictive tools derived from prior Guillain-Barré syndrome studies include the Erasmus Guillain-Barré syndrome outcome score at 2 weeks and the modified Erasmus Guillain-Barré syndrome Outcome Score at week 1. & Patients and their families can be advised about the long-term prognosis as early as 1 or 2 weeks as well as risk of respiratory failure in the first week of admission by 2using the online IGOS GBS Prognosis Tool. & A temporal variant group consists of patients who progress for longer than 4 weeks but less than 8 weeks, and therefore do not fall neatly into either AIDP or chronic inflammatory demyelinating polyneuropathy groups. & In one study, subacute inflammatory demyelinating polyneuropathy (SIDP) patients were treated with prednisone and some received an IVIg course as well; all improved and were able to taper off and stop prednisone. Definite SIDP had all of the CIDP characteristics with three exceptions: a higher rate of antecedent infection, no relapses, and a high rate (69%) of full recovery. & The chronic acquired demyelinating polyneuropathies are immune-mediated neuropathies with a number of common features. & Although patients with chronic acquired demyelinating polyneuropathies may have exclusively distal weakness, when only distal clinical features are present, the differential diagnosis is much broader and includes toxic, metabolic, hereditary, and vasculitic disorders. & When symmetric proximal and distal involvement is not present, the likelihood of identifying a treatable demyelinating disorder is lower. & CIDP is caused by immune-mediated demyelination. The precise pathophysiology has not been elucidated, but T-cell activation is the predominant factor. Important roles are also played by macrophages and humoral factors. & The three most important laboratory studies that support the diagnosis of CIDP are CSF examination, nerve conduction studies, and nerve biopsy. & CSF testing is not necessary in every patient suspected of CIDP; however, all patients with suspected CIDP should be checked for a serum paraprotein. & In most patients with CIDP, a nerve biopsy is not necessary. & While nerve conduction study is an important and useful tool, the overall clinical presentation is most helpful in a making a diagnosis. & Sensory nerve conduction studies currently have no accepted role in establishing a diagnosis of a demyelinating polyneuropathy. & The studies comparing criteria are all limited by retrospective evaluation and lack of a gold standard. & The purpose of nerve conduction study criteria is to minimize the number of patients without demyelinating neuropathies from being falsely diagnosed with CIDP while not excluding too many patients who do have CIDP. & Randomized, controlled trials have demonstrated the efficacy of corticosteroids, plasma exchange, and IVIg for the treatment of CIDP. The efficacy of these therapies appears to be similar. Each is an acceptable first-line therapy, although the need for facilities capable of providing outpatient plasma exchange and prolonged IV access usually relegates plasma exchange to a second-or third-line agent. & The ideal IVIg treatment regimen has not been determined. The most common strategy is to give a loading dose of 2 g/kg. This is usually administered over 2 to 5 days, with most patients able to receive this dose over 2 days. & Some form of repeat IVIg dosing is necessary, because, in most cases, it can take an average of 3 months for maximal improvement to occur. & Approximately two-thirds of CIDP patients will improve with IVIg. & Although patients with CIDP can be maintained on long-term IVIg treatment, most experts advocate trying to decrease or discontinue IVIg. & Clinical trial data show that approximately 50% of patients with CIDP will remain stable at least 6 months after IVIg is stopped, but the other 50% will deteriorate and require a resumption of treatment. & Plasma exchange is often used for patients with CIDP who are very weak or experience a relapse while on another therapy. However, plasma exchange can be used as a long-term therapy. & While retrospective series suggest about one-third of patients with CIDP will respond to other immunomodulating medications, high-level evidence for these therapies does not exist, and many are skeptical of their efficacy. Therefore, the preference of the authors of this article is to use IVIg, corticosteroids, and plasma 
Abstract
Purpose of Review:
Infections are important, potentially treatable causes of peripheral nervous system disease. This article reviews the clinical presentation and management of several common peripheral nervous system diseases due to viral, bacterial, spirochetal, and parasitic infections.
Recent Findings:
The clinical presentation and evaluation of infectious peripheral nervous system diseases are well established. Advances in the treatment and, in some cases, the prevention of these diseases are still evolving.
Summary:
A diverse range of peripheral nervous system diseases, including peripheral neuropathy, radiculopathy, radiculomyelopathy, cranial neuropathy, and motor neuropathy, are caused by bacterial, viral, and parasitic infections. In some patients, peripheral neuropathy may be a side effect of anti-infectious drugs. This article discusses the clinical presentation, evaluation, and treatment of patients with infectious peripheral nervous system diseases. Numerous infectious agents can cause peripheral nervous system disease; infectious neuropathies are important to recognize as they are potentially treatable. This article discusses several common peripheral nervous system diseases caused by viral, bacterial, spirochetal, and parasitic infections, as well as some peripheral nerve disorders caused by adverse effects of the treatments of these infectious diseases. within a spectrum from tuberculoid disease (in which the skin lesions are few, the sensory loss more confined to the cutaneous lesion, and the organisms difficult to demonstrate) to lepromatous disease (in which the skin lesions are numerous, the sensory loss more generalized, and the organisms are prominent on smear or biopsy). & In contrast to length-dependent polyneuropathies, leprosy presents with relative sparing of tendon jerks, position and vibratory sense, and noncutaneous autonomic function. & Mycobacterium leprae is responsive to antibiotics. Once the diagnosis is confirmed, treatment should be initiated promptly with a multidrug regimen to prevent progressive neuropathy, late sequelae, and spread of the disease to others. & Lyme disease is caused by a tick-borne spirochete, Borrelia burgdorferi. In North America, the disease is endemic in the Northeast, northern Midwest, and West. & Lyme disease begins when the tick transmits the organism to the skin, resulting in a characteristic skin rash (erythema migrans). If untreated, early localized disease in the skin may become hematogenously disseminated to the nervous system. & Early neurologic Lyme disease is distinctive with one or more components of the characteristic triad: meningitis, cranial neuritis, and radiculoneuritis. A smaller number of patients may develop a milder, sensorimotor polyradiculoneuropathy typically occurring later in the course of the illness. & All neuroborreliosis syndromes are responsive to 2 to 4weeks of antibiotics. Residual symptoms do not respond to continued courses of antibiotics.
Key Points
& Acquiring a detailed history is crucial to diagnosis of neuropathies caused by toxic agents and vitamin deficiencies. & In a neuropathy with significant asymmetry, polyradicular, or mononeuritis multiplex presentation, other etiologies should be explored further, even in the setting of documented toxicity or vitamin deficiency. & Causes for vitamin B 12 deficiency include pernicious anemia, strict veganism, gastric bypass, prolonged antacid use, atrophic gastritis, or diseases of the terminal ileum (eg, resection, Crohn disease). & Copper deficiency may look very clinically similar to vitamin B 12 deficiency and should be investigated in parallel with patients with a myeloneuropathy presentation. & Vitamin B 6 is unusual in that it is associated with peripheral neuropathy either when deficient or in excess. & Neuropathy due to thiamine deficiency has many presentations, including length-dependent sensorimotor, cranial nerve, and motor-predominant polyneuropathy, all of which may precede cognitive and systemic symptoms. & It has been difficult to determine whether alcohol directly causes neuropathy or if its association with neuropathy is due more to chronic malnutrition and vitamin deficiencies in alcoholics. & Intoxication from arsenic or thallium is preceded by severe gastrointestinal illness, and the neuropathy may mimic Guillain-Barré syndrome. & Toxic exposure from industrial agents may be more likely to occur in people using these agents for personal use or in small businesses. & Newer chemotherapy agents approved over the past several years continue to have frequent side effects of peripheral neuropathy.
& Ingestion of toxic seafood may be associated with peripheral nerve disorders, which often presents as a syndrome of gastroenteritis and perioral paresthesia.
Paraproteinemic Neuropathies
Mauermann, Michelle L. MD. Continuum (Minneap Minn). October 2014; 20(5 Peripheral Nervous System Disorders): 1307Y1322.
Abstract
Monoclonal gammopathies are common in the general population and occur in 10% of patients with peripheral neuropathy. It is important for the clinician to be able to determine whether an association exists between the paraprotein and the neuropathy. The clinical phenotype of the neuropathy, as well as the type of monoclonal protein, provides clues for the diagnosis. Optimal management of paraproteinemic neuropathies requires appropriate evaluation of the monoclonal protein for an underlying hematologic disorder.
Recent Findings:
Clinical studies in paraproteinemic neuropathies have provided a better understanding of these disorders, but much is still unknown regarding the pathophysiologic mechanisms. Recent clinical trials in immunoglobulin M (IgM) neuropathy have shown that better outcome measures and treatment approaches are needed. Peripheral blood stem cell transplantation has shown promising improvements in the treatment of polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, and skin changes (POEMS) syndrome and immunoglobulin light chain (AL) amyloidosis.
Summary:
Recognizing the frequent association of neuropathy with monoclonal proteins and evaluating for a hematologic malignancy should enable physicians to find better treatments and ultimately improve neuropathy outcome. transverse process fracture, and proximal first rib fracture. & Although MRI is less sensitive than CT myelography for root avulsion, its multiplanar imaging and tissue-differentiating abilities, lack of radiation and bone-related image degradation, and its noninvasiveness render it the radiologic procedure of choice for more distal lesions. & Because greater force is required to damage both the brachial plexus elements and the vascular elements, brachial plexus lesions with concomitant vascular injury tend to have a worse prognosis. & Because each element of the brachial plexus carries unique sensory and motor axons, focal plexopathies typically are associated with unique electrodiagnostic features. & All three portions of the electrodiagnostic examinationYYthe sensory nerve conduction studies, the motor nerve conduction studies, and the needle EMGYYare performed because each yields information not provided by the others. & In addition to differentiating preganglionic and postganglionic lesions, the pattern of sensory nerve action potential abnormalities has localization utility. & The temptation to grade severity by fibrillation density must be resisted because it is more reflective of study timing and, to a lesser extent, the innervation ratio of the muscle under study. & With true neurogenic thoracic outlet syndrome, because the band angulates the lower plexus from below, the T1 axons are affected to a greater extent than the C8 axons. This produces localizing clinical and electrodiagnostic features that are nearly pathognomonic. & The presence of a cervical rib is not synonymous with true neurogenic thoracic outlet syndrome because the incidence of cervical ribs is 20,000 to 80,000 times higher than that of true neurogenic thoracic outlet syndrome. & Because the C8 dorsal root ganglion contributes ulnar sensory axons via the C8 anterior primary ramus, lesions of the C8 anterior primary ramus often mimic an ulnar neuropathy. & When unrecognized, postYmedian sternotomy plexopathy may be misdiagnosed as an ulnar neuropathy, potentially leading to an unnecessary surgical procedure and misdirected blame. & The motor axon predilection of neuralgic amyotrophy explains why the suprascapular, long thoracic, axillary, and musculocutaneous nerves are the most frequently affected proximally and why the motor nerve branches to individual muscles are most affected distally.
Key Points
especially after hip surgery; ischemia; inflammation; infiltration (amyloid); and idiopathic causes. & Often, the pathologic involvement of lumbosacral plexopathy is not limited to the lumbosacral plexus and also involves the root and the nerve levels. These conditions are not pure lumbosacral plexopathies but are lumbosacral radiculoplexus neuropathies. & Most neoplastic causes of lumbosacral plexopathies involve the plexus through direct spread by local intrapelvic organs (eg, colon, ovaries, cervix, bladder), but in some cases (prostate), the tumor spreads within the confines of the nerve and spreads longitudinally (perineurial spread). & The lumbosacral plexus can be divided into the upper lumbar plexus and the lower lumbosacral plexus. Each may be affected separately by a local lesion, but a diffuse lesion usually causes more generalized involvement. & Pain located in the back, hip, or buttock is often a presenting symptom of neoplastic lumbosacral plexopathy and usually starts long before the patient develops muscle weakness or sensory loss. & Local infection at the psoas muscle or adjacent retroperitoneal space, such as abscess in the psoas muscle or the gluteal region, can affect the lumbosacral plexus. & The trauma that causes traumatic lumbosacral plexopathy is usually severe, involves very high velocity and energy at the time of impact, and is associated with pelvic fractures. & Late radiation-induced lumbosacral plexopathy can occur many years (up to decades) after the radiation treatment. A patient usually presents with very slowly progressive muscle weakness and atrophy with or without sensory loss (which is typically minimal if present) and usually has no pain in contrast to neoplastic lumbosacral plexopathy. & Myokymic discharges on needle examination are highly suggestive of a radiation-induced lumbosacral plexopathy, but their presence does not exclude recurrent malignancy. & Retroperitoneal hematoma affecting the psoas muscle can cause lumbosacral plexopathy and may be related to various causes, either traumatic or nontraumatic, such as hemophilia, anticoagulant use, or hematologic malignancy. & The symptoms of diabetic lumbosacral radiculoplexus neuropathy, lumbosacral radiculoplexus neuropathy, and postsurgical inflammatory neuropathy causing lumbosacral plexopathy usually consist of acute to subacute onset of severe pain and paresthesia, followed by motor weakness of proximal and distal segments beginning focally and unilaterally but progressing bilaterally but asymmetrically. These symptoms are usually associated with weight loss. & The pathophysiologic cause of diabetic lumbosacral radiculoplexus neuropathy, lumbosacral radiculoplexus neuropathy, painless motor and lower limb predominant diabetic neuropathy, and postsurgical inflammatory neuropathy causing lumbosacral plexopathy is ischemic injury and microvasculitis. & One form of diabetic lumbosacral plexopathy presents as painless lower limb and motor predominant neuropathy. Patients with this form present more slowly and symmetrically with greater degree of weakness than typical painful diabetic lumbosacral radiculoplexus neuropathy. Nonetheless, they have diabetic lumbosacral radiculoplexus neuropathy and not diabetic CIDP. & Postsurgical inflammatory neuropathies often present as lumbosacral plexopathies, can occur ipsilaterally or contralaterally to the surgical site, and may be missed because they are thought to be due to stretch or compressive causes. They are recognized by neuropathy progression in the postoperative period and confirmed by inflammatory infiltrates on nerve biopsy.
& The electrophysiologic definition of a lumbosacral plexopathy is involvement of muscles from at least two lumbosacral root levels from at least two peripheral nerves. In a pure lumbosacral plexopathy, fibrillation potentials of the lumbosacral paraspinal muscles are not present, whereas in a lumbosacral radiculoplexus neuropathy, fibrillation potentials in paraspinal muscles are present. & Although a controlled trial of IV methylprednisolone did not improve impairments, it did improve pain and other sensory symptoms in diabetic lumbosacral radiculoplexus neuropathy, so the authors of this article include corticosteroids in their management of patients with diabetic lumbosacral radiculoplexus neuropathy, lumbosacral radiculoplexus neuropathy, and postsurgical inflammatory neuropathy causing lumbosacral plexopathy.
& Only about 20% of all cases of sensory neuronopathy are related to an underlying malignancy. The rest are either idiopathic, associated with autoimmune disorders (especially Sjögren syndrome), or toxic due to chemotherapy agents. & In suspected sensory neuronopathy, routine nerve conduction studies will reveal normal motor responses, with either absent sensory responses or severely diminished sensory amplitudes. & Patients with paraneoplastic enteric neuropathy present with severe constipation, nausea, early satiety due to lack of gastric emptying, abdominal distention, and weight loss. & In paraneoplastic motor neuropathy, patients present with slowly progressive painless asymmetric weakness in the limbs. Bulbar involvement is not common, and there are no upper motor neuron features; these characteristics help differentiate it from neurodegenerative causes of motor neuron disease (such as ALS). & It is important to recognize that lymphomas may also cause neuropathy secondary to direct infiltration of the nerve roots rather than a paraneoplastic phenomenon. neuropathies. These should be considered primarily when patients continue to worsen after the underlying malignancy has been treated or in patients where there is no tissue diagnosis of cancer. & IV immunoglobulin therapy was studied in various open-label studies, but the effectiveness is difficult to determine because there were no control group comparisons and IV immunoglobulin was given along with other immunomodulatory therapies.
recognize these disorders, identify potentially reversible or treatable causes, and implement the appropriate treatment as well as supportive care.
Recent Findings:
Secondary forms of autonomic neuropathies (eg, diabetes mellitus, amyloidosis) are much more common than primary forms, of which autoimmune ganglioneuropathies represent a major component. However, the spectrum of the latter is continuously evolving and has diagnostic and therapeutic implications. Testing modalities such as autonomic testing, serum autoimmune antibody testing, and skin biopsies are becoming more widely available.
Summary:
Autonomic neuropathies are relatively common conditions, and, because of the prognostic implications as well as impact on patient quality of life, they should be promptly recognized and treated aggressively. Testing is critical as other conditions may mimic autonomic neuropathies. Treatment is symptomatic in many cases, but specific therapies are also available in selected autonomic neuropathies. 
Key Points
Abstract
Purpose of Review:
This article reviews the clinical, neurophysiologic, and neuropathologic findings in patients presenting with small fiber neuropathies. Emphasis is placed on recent updates to the literature, but also on understanding the differential diagnosis and initial evaluation of patients with small fiber neuropathy.
Recent Findings:
There have been several updates in the literature about diseases associated with small fiber neuropathy. First, treatment-induced neuropathy in diabetes mellitus is an iatrogenic small fiber neuropathy linked to overly rapid correction in blood glucose levels in the setting of chronic hyperglycemia. Second, several novel mutations to sodium channels have been identified in patients presenting with idiopathic small fiber neuropathy that may significantly alter our understanding and future treatment of small fiber neuropathy. Third, antibodies against voltage-gated potassium channels appear to be associated with a much higher incidence of pain than would be expected, although the mechanism has not been established. Fourth, the link between glucose dysregulation, metabolic syndrome, and neuropathy continues to grow. Finally, several other disorders, including postural tachycardia syndrome, have been postulated to be associated with small fiber neuropathies.
Summary:
Small fiber neuropathies are a heterogeneous group of disorders that may present with a variety of sensory or autonomic symptoms. Recent reports highlight a number of new causes of small fiber neuropathy that continue to reduce the number of remaining idiopathic cases. 
Key Points
Abstract
Purpose of Review:
This article reviews the clinical presentations, diagnostic findings, and treatment options for autoimmune myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome.
Recent Findings:
Immunologic research is unraveling the immunopathology of MG and identifying targets for novel immune-based therapy of this condition. MG patients with antibodies to muscle-specific tyrosine kinase (MuSK) frequently present with symptoms and clinical findings that suggest nerve or muscle disease.
Summary:
Early diagnosis and treatment have a marked effect on outcome in these diseases. In most cases, the diagnosis of MG or Lambert-Eaton myasthenic syndrome can be made from the history, supplemented with directed questions, and a physical examination designed to demonstrate variable weakness in affected muscle groups. Appropriate confirmatory tests almost always establish the diagnosis. Although several novel treatment modalities for MG are under investigation, currently available therapies produce substantial improvement in function and quality of life in most patients with this condition. Knowledge about the dosing, adverse effects, and costs of immunomodulatory therapies is essential for the effective management of patients with MG and Lambert-Eaton myasthenic syndrome.
Key Points
& Myasthenia gravis with acetylcholine receptor antibodies is the most common neuromuscular junction disorder. It typically presents with fluctuating, fatigable ocular symptoms, and signs that are frequently ascribed to CNS disease.
& Muscle-specific tyrosine kinase (MuSK) myasthenia gravis usually affects young females and may have clinical findings suggestive of nerve or muscle disease. Suspect MuSK myasthenia gravis if there is isolated head drop, facial muscle or tongue weakness and atrophy, or weakness that predominates in neck or shoulder muscles. & Patients and clinicians should be aware of and avoid medications known to exacerbate myasthenia gravis and Lambert-Eaton myasthenic syndrome weakness. & Examination of patients with suspected myasthenia gravis should focus on demonstrating fatigable weakness in affected muscle groups with particular attention to ocular muscles. Eyelid ptosis that shifts from one eye to the other is virtually diagnostic of myasthenia gravis. The weakness in myasthenia gravis typically comes and goes and may not be present during the examination. & The edrophonium test is positive in 90% of myasthenia gravis patients. Improvement in lid ptosis, oculomotor weakness, or both are usually produced with 2 mg to 3 mg. Patients with muscle-specific tyrosine kinase (MuSK) myasthenia gravis may become worse or develop profuse fasciculations after edrophonium. & Acetylcholine receptor antibodies are present in most myasthenia gravis patients, but in only about 50% of those with weakness limited to ocular muscles. Consider testing for muscle-specific tyrosine kinase (MuSK) antibodies if acetylcholine receptor antibodies are not found and in patients with prominent bulbar, proximal extremity, or respiratory weakness. & EMG studies of neuromuscular transmission are most likely to be abnormal in clinically involved muscles in myasthenia gravis. & Chest imaging should be performed in patients with myasthenia gravis to exclude thymoma, which is unlikely unless acetylcholine receptor antibodies are elevated. & Muscle-specific tyrosine kinase (MuSK) myasthenia gravis patients often require more aggressive immunosuppression, particularly early in the course of the disease. Consider rituximab in these patients. & Lambert-Eaton myasthenic syndrome is characterized by the triad of weakness, dry mouth, and reduced or absent tendon reflexes. Weakness on examination is frequently less than the symptoms would suggest. & Lambert-Eaton myasthenic syndrome patients should have an initial malignancy workup. If negative, this should be repeated periodically depending on the patient's risk of cancer. & Amifampridine is a mainstay of treatment for patients with Lambert-Eaton myasthenic syndrome; acetylcholinesterase inhibitors and immunosuppression are usually much less effective.
